The second MidWest Drug Development conference held in 2019 was another resounding success.

The conference featured 42 technology presentations from 18 Midwestern universities, and 30 different companies and investor groups. An estimated 240 one-on-one partnering meetings were held during the two-day event, opening the door to additional opportunities for each participating university.

“I know we got a lot of value out of the conference, and I’ve had nothing but positive feedback from just about everyone I talked to,” said Matt Boehm, the event coordinator and director of licensing for UNeMed, the technology transfer and commercialization office for the University of Nebraska Medical Center. UNeMed is also the primary sponsor and host of the event.

Boehm added that he sat in on 17 one-on-one partnering meetings during the event, resulting in ongoing conversations that may yet lead to further development.

“That’s exactly what we want this conference to do,” UNeMed president and CEO Michael Dixon said. “New therapies, treatments and cures are the kind of things that can grow out of those deeper conversations. And, honestly, I think there’s a huge blind spot for the innovation that happens in the Midwest, and we really want this conference to help change that. Not just for us in Nebraska, but for all our friends in the region.”

Major medical research and research institutions in Midwestern states will bring their best and brightest

Top decision makers from the world’s leading pharmaceutical companies and investment groups will gather for a look at the most promising therapeutic discoveries and innovations in the Midwest United States